This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Company News for Mar 4, 2025
by Zacks Equity Research
Companies In The News Are: CRC, TGTX, NOMD, BHVN.
TGTXNegative Net Change CRCPositive Net Change NOMDNegative Net Change BHVNNegative Net Change
biotechnology consumer-staples oil-energy
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug
by Zacks Equity Research
The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.
REGNPositive Net Change RHHBYPositive Net Change BMRNNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
by Zacks Equity Research
Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
BMRNNegative Net Change GILDNegative Net Change FOLDNegative Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues
by Zacks Equity Research
APLS reports better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
BMRNNegative Net Change GILDNegative Net Change FOLDNegative Net Change APLSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Best Momentum Stocks to Buy for March 3rd
by Zacks Equity Research
STRL. BATRA and JAZZ made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 3, 2025.
JAZZNegative Net Change STRLNegative Net Change BATRANegative Net Change
biotechnology
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta
by Zacks Equity Research
The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved treatment.
NVSPositive Net Change BMRNNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus
by Zacks Equity Research
CYTK reports a wider-than-expected Q4 loss as operating expenses increase. CYTK is gearing up to launch lead candidate aficamten upon a potential FDA approval.
SNYPositive Net Change BAYRYNegative Net Change CYTKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus
by Zacks Equity Research
DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for tividenofusp alfa for the treatment of MPS II (Hunter syndrome).
SNYPositive Net Change BIIBNegative Net Change DNLINegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027.
SNYPositive Net Change BMRNNegative Net Change GILDNegative Net Change KYMRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira Q4 Earnings Top, Revenues Miss Despite Exparel Sales Growth
by Zacks Equity Research
PCRX reports mixed fourth-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
BMRNNegative Net Change GILDNegative Net Change FOLDNegative Net Change PCRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
After Golden Cross, Option Care (OPCH)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
OPCHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Annaly Capital Management (NLY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
NLYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
BMRNNegative Net Change GILDNegative Net Change NBIXNegative Net Change XENEPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Q4 Earnings and Revenues Miss Estimates, Stock Plunges
by Zacks Equity Research
VTRS Q4 earnings and sales miss estimates. The guidance for 2025 looks disappointing due to the financial impact of the Indore facility warning letter and import alert. Stock down.
BMRNNegative Net Change GILDNegative Net Change FOLDNegative Net Change VTRSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth
by Zacks Equity Research
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
BMRNNegative Net Change GILDNegative Net Change FOLDNegative Net Change ACADNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy First Industrial Realty Trust (FR) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
FRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
CPRX Q4 Earnings Beat, Firdapse Sales Boost Revenues, Stock Up
by Zacks Equity Research
Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
BMRNNegative Net Change GILDNegative Net Change FOLDNegative Net Change CPRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
BMRNNegative Net Change BEAMPositive Net Change FOLDNegative Net Change MDGLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA
by Zacks Equity Research
BLUE and GILD are in the spotlight this week on key updates.
BMRNNegative Net Change GILDNegative Net Change TRDANegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
by Ekta Bagri
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their portfolio.
RDYNegative Net Change RIGLPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
SANA Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Sana Biotechnology's Q4 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.
PCRXNegative Net Change ARGXPositive Net Change MIRMNegative Net Change SANAPositive Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Nextracker (NXT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
NXTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
by Zacks Equity Research
Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
JNJPositive Net Change BMRNNegative Net Change FOLDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
What's in Store for These 5 Biotech Stocks This Earnings Season?
by Ahan Chakraborty
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
PRGONegative Net Change NVAXPositive Net Change NTLANegative Net Change IOVANo Net Change VTRSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals vaccines
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
by Ekta Bagri
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth.
RDYNegative Net Change RIGLPositive Net Change
biotechnology biotechs medical pharmaceuticals